REMS
Contraindicated in:
Use Cautiously in:
Derm: facial flushing, rash
EENT: nasal onlyrhinitis, epistaxis, nasal irritation
GU: IM, SUBQurinary frequency
Local: injection site reactions
MS: nasalarthralgia, back pain
Neuro: nasal onlyheadaches
Misc: MALIGNANCY, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
Drug-drug:

Postmenopausal osteoporosis
Pagets disease
Hypercalcemia
Absorption: Completely absorbed from IM and SUBQ sites. Rapidly absorbed from nasal mucosa; absorption is 3% compared with parenteral administration.
Distribution: Unknown.
Half-Life: 4090 min.
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| IM, SUBQ‡ | unknown | 2 hr | 68 hr |
| Intranasal‡ | rapid | 3139 min | unknown |
‡Effects on serum calcium; effects on serum alkaline phosphates and urinary hydroxyproline in Paget's disease may require 624 mo of continuous treatment.
‡Serum levels of administered calcitonin.